Marinomed Biotech AG (VIE:MARI)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Virology	11.20M	9.69M
Virology Growth	15.59%	19.83%
Immunology	-	1.91M
Immunology Growth	-	4805.13%
Other	77.70K	26.80K
Other Growth	189.93%	5260.00%
Total	11.28M	11.63M
Total Growth	-3.03%	43.12%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Austria	541.00K	335.00K	536.00K	987.50K	603.40K
Austria Growth	61.49%	-37.50%	-45.72%	63.66%	36.76%
Other European Countries	6.69M	3.38M	4.46M	6.86M	5.87M
Other European Countries Growth	98.10%	-24.34%	-34.92%	16.79%	10.42%
Non-European Countries	462.00K	1.04M	4.06M	3.43M	5.15M
Non-European Countries Growth	-55.41%	-74.48%	18.28%	-33.40%	117.75%
Total	7.69M	4.75M	9.06M	11.28M	11.63M
Total Growth	62.02%	-47.59%	-19.67%	-3.03%	43.12%

Source: S&P Global Market Intelligence.